MoonLake Immunotherapeutics
MLTX
$3.28
Change (1 day)
$64.98
Year High
$35.11
Year Low
Categories
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Earnings for MoonLake Immunotherapeutics (MLTX)
Earnings in 2023 (TTM): $-43,984,729
According to MoonLake Immunotherapeutics's latest financial reports the company's current earnings (TTM) are $-43,984,729. The earnings displayed on this page is the company's Pretax Income.
Earnings history of MoonLake Immunotherapeutics
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-43,984,729 | $-36,007,260 |
| 2022 | $-64,469,685 | $-64,506,051 |
| 2021 | $-53,638,860 | $-53,643,615 |
| 2020 | $-90,838 | $-90,838 |